Dr. Claire Verschraegen
Professor of Medicine, Director, Hematology/Oncology Division
89 Beaumont Avenue, Suite E-214
Burlington, VT 05405
Free University of Brussels
Universite Libre De Bruxelles - 1982
University of Texas Science Center and M.D. Anderson Cancer Center
Clinique L. Caty
Considered one of the United States' leading experts in malignant peritoneal mesothelioma, a rare form of asbestos-caused cancer, Dr. Claire Verschraegen is a native of Belgium and is currently a Professor of Medicine at the University of Vermont and Director of the Division of Hematology and Oncology at the Vermont Cancer Center in Burlington, Vermont.
Dr. Vershraegen did her undergraduate work at the Free University of Brussels and earned her medical degree from the Universite Libre De Bruxelles in 1982. After graduation, she completed her internship and residency training at the University of Texas Science Center and the M.D. Anderson Cancer Center, and a fellowship in internal medicine at Clinique L. Caty in her home country of Belgium. As part of her training, Verschraegen also spent three years at the Stehlin Foundation for Cancer Research, where she was under the tutelage of Dr. Beppino Giovanella.
Dr. Verschraegen is board certified in internal medicine and medical oncology in America as well as in Belgium. As a doctor, she focuses on the treatment of not only peritoneal mesothelioma but also a variety of gynecological and appendiceal cancers. In particular, her research largely involves the study of emerging chemotherapy drugs designed to treat a variety of cancers. She has conducted extensive research of the chemotherapy drug Alimta® used in tandem with gemcitabine for the treatment of malignant peritoneal mesothelioma.
Affiliations and Publications
Verschraegen is a member of the Mesothelioma Applied Research Foundation and as such has appeared as guest or keynote speaker at a number of mesothelioma-centered symposiums, conferences, workshops, and meetings sharing information with both mesothelioma doctors and their patients. A former Fulbright scholar, she has penned more than 80 peer-reviewed papers, 10 book chapters, and 20 invited papers. Her studies and expertise have also earned Dr. Verschraegen the Occino-Kernkamp Prize from the Belgium Association of University Women.
University of New Mexico Cancer Center